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the toxicity pattern reflected by transcript changes be com-
pacted/dimensionality-reduced for practical regulatory use; 
(3) how can a reduced set of biomarkers be selected for 
large-scale follow-up? Transcript profiling allowed clear 
separation of different toxicants and the identification of 
toxicant types in a blinded test study. We also developed 
a diagrammatic system to visualize and compare toxic-
ity patterns of a group of chemicals by giving a quantita-
tive overview of altered superordinate biological processes 
(e.g. activation of KEGG pathways or overrepresentation 
of gene ontology terms). The transcript data were mined 
for potential markers of toxicity, and 39 transcripts were 
selected to either indicate general developmental toxicity 
or distinguish compounds with different modes-of-action 
in read-across. In summary, we found inclusion of tran-
scriptome data to largely increase the information from the 
MINC phenotypic test.
Keywords Developmental toxicity · Alternative testing · 
Transcriptome profiling · Neural crest cells
Abbreviations
BH  Benjamini–Hochberg method for p value 
adjustment for multiple comparisons
BOT  Biomarker of toxicity
DEG  Differentially expressed genes
ESNATS  Embryonic stem cell-based novel alternative 
tests
FC  Fold change
GA  Geldanamycin
GO  Gene ontology
HDACi  Histone deacetylase inhibitor
hESC  Human embryonic stem cell
HSP  Heat-shock protein
KEGG  Kyoto encyclopaedia of genes and genomes
Abstract The in vitro test battery of the European 
research consortium ESNATS (‘novel stem cell-based test 
systems’) has been used to screen for potential human 
developmental toxicants. As part of this effort, the migra-
tion of neural crest (MINC) assay has been used to evalu-
ate chemical effects on neural crest function. It identified 
some drug-like compounds in addition to known environ-
mental toxicants. The hits included the HSP90 inhibitor 
geldanamycin, the chemotherapeutic arsenic trioxide, the 
flame-retardant PBDE-99, the pesticide triadimefon and the 
histone deacetylase inhibitors valproic acid and trichostatin 
A. Transcriptome changes triggered by these substances in 
human neural crest cells were recorded and analysed here 
to answer three questions: (1) can toxicants be individu-
ally identified based on their transcript profile; (2) how can 
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LUHMES  Lund human mesencephalic
MINC  Migration of neural crest cell
NC  Neural crest
NSPC  Neural stem and progenitor cells
PBDE  Polybrominated diphenyl ether
PCA  Principal component analysis
PCB  Polychlorinated biphenyl
PS  Probe set
SVM  Support vector machine
TDF  Triadimefon
TSA  Trichostatin A
VPA  Valproic acid
Introduction
Stem cell-based in vitro test systems offer new possibili-
ties to explore toxicological hazard directly on relevant and 
non-transformed human cells. This novel approach particu-
larly benefits some complex toxicological areas, such as 
developmental toxicity, that have not been accessible in the 
past to human-relevant testing.
Besides the three germ layers forming the different tis-
sues and organs, a so-called fourth layer plays a role in this 
complex stage: the neural crest (NC). The NC is a multipo-
tent migratory cell population that emerges from the dorsal 
aspect of the neuronal tube in the early phases of develop-
ment and gives rise to a multitude of different cell types, 
supporting the formation of cartilage, bone, connective tis-
sue of the face, but also neurons, glial cells, melanocytes 
and cardiomyocytes (Huang and Saint-Jeannet 2004). A 
large percentage of developmental disorders (e.g. congeni-
tal heart defects, orofacial clefts, Hirschsprung’s disease) 
are caused by NC cells (NCC) deficit, and these often cor-
relate with neural tube defects. This kind of alterations can 
be induced by genetic factors (Lee et al. 2009) or exposure 
to pharmaceuticals (e.g. valproic acid, Fuller et al. 2002) 
and pesticides (e.g. triadimefon, Menegola et al. 2000).
In the field of in vitro DNT testing, a new approach is 
being explored, based on the use of human cells and on 
the identification and modelling of distinct key biological 
processes representing possible targets of a toxicant. The 
effects of a toxicant may be described as the set of altera-
tions of endpoints in such test systems. Examples for such 
test systems are the neurite outgrowth assay (Krug et al. 
2013a) and the neural crest cell migration (MINC) assay 
(Zimmer et al. 2012; Dreser et al. 2015). These two exem-
plary assays are based on the quantification of a functional 
endpoint (neurite outgrowth and number of migrated cells) 
in relevant biological systems (LUHMES-derived neurons 
and human embryonic stem cell (hESC)-derived NCC).
Other test systems explore, e.g., changes of neural dif-
ferentiation (Balmer et al. 2012), gliogenesis (Fritsche 
et al. 2005), myelination (Zurich et al. 2000, 2002) or syn-
aptogenesis (Harrill et al. 2011). Usually, the test systems 
also address defined developmental stages (Stummann 
et al. 2009; van Dartel et al. 2009; Zimmer et al. 2011).
Therefore, in vitro testing strategies usually require 
a battery of tests (Leist et al. 2014; Bal-Price et al. 2015; 
Rovida et al. 2015) in order to cover most of the key bio-
logical and molecular events.
Different types of test batteries have been recently pre-
sented: they may consist of molecular-based assays, like in 
the ToxCast program (Sipes et al. 2011; Padilla et al. 2012) 
or cell-based assays, as, for example, in the ReProTect 
(Schenk et al. 2010) or ChemScreen (van der Burg et al. 
2014, 2015) projects.
A further step into this direction was taken by the 
ESNATS consortium with the establishment of a stem 
cell-based test battery (Zimmer et al. 2014). This test-
ing approach was designed in a modular way to allow any 
interested user to join in and to add their test system as well 
as the data generated from it. The ESNATS test battery has 
some features that distinguish it from earlier approaches, 
the two most important ones referring to the test chemicals 
selection and to the follow-up procedure of positive screen 
results (hits).
The usual approach of test chemical selection for new 
assays (Leist et al. 2010; Crofton et al. 2011; Kadereit et al. 
2012) is based on the compilation of chemicals with prede-
fined activity (i.e. known positives and negatives) to be used 
as gold standard to calibrate the assay. This approach is dif-
ficult for in vitro test systems of developmental toxicity for 
two reasons. First, only few such gold-standard compounds 
are known from reliable in vivo studies or human epidemi-
ology; second, also for known compounds, it is often not 
clear how they are expected to behave in an in vitro sys-
tem. To get out of this dilemma, other approaches of assay 
validation and selection of initial test compound sets have 
been suggested (Leist et al. 2012a; Hartung et al. 2013; 
Smirnova et al. 2014). In essence, such alternative strate-
gies comprise two steps: first, the test system undergoes 
mechanistic validation on the basis of tool compounds that 
verify that the expected biochemical features and signal-
ling pathways are represented by the system; second, once 
trust in the biological relevance of the systems is estab-
lished, a broad set of interesting compounds can be tested. 
These chemicals are then classified as potentially hazard-
ous (or not), based on the outcome of the screen (Behl 
et al. 2015; Pei et al. 2015). Thus, this approach takes the 
opposite direction from the classical approach. The advan-
tage of this strategy is that a broad range of compounds 
is characterized for a potential developmental toxicity 
hazard, ideally across multiple test systems (test battery). 
When chemicals are identified as developmental toxicity 
hazard, they can be used as gold standards for further test 
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system establishment, and consequently, the pool of well-
characterized compounds required for test system set-up 
grows. The ESNATS test battery (Zimmer et al. 2014) and 
a 76-compound library of the national toxicology program 
of the USA (Pei et al. 2015) were set up with this goal in 
mind.
The test compound list of the ESNATS battery com-
prised 28 substances, including biologics, pharmaceuti-
cals and environmental toxicants. The background data 
of these compounds were extensively documented, for 
instance concerning general cytotoxic potency, chemical 
and pharmacokinetic data, as well as further relevant find-
ings retrieved by literature data mining. In 2014, a first 
screening was performed using one of the assays included 
in the test battery, i.e., by the migration inhibition of neu-
ral crest cells (MINC) assay. This test was included in the 
ESNATS test battery project (as UKN2 system) to cover 
the developmental stage of neural crest with a cell func-
tion-specific endpoint (migration; Zimmer et al. 2012). 
The MINC screening led to the identification of 11 hits, 
comprising all of the environmental chemicals (positive 
controls) and some little-characterized pharmaceuticals. In 
contrast to some other screening algorithms, the ESNATS 
test battery scheme consists of an extensive part of hit fol-
low-up to further characterize the chemicals and their effect 
in the test system. This is considered an important activ-
ity towards the overall objective of identifying new poten-
tial gold-standard developmental toxicants on the basis of 
their in vitro effects. One of the follow-up activities firmly 
anchored in the test battery scheme is the full characteriza-
tion of transcriptome changes triggered by the hits. In this 
context, it is important to note that the hits of the MINC 
assay are chosen because of their functional effects in the 
test system, i.e. because they inhibit a cell function consid-
ered to be essential for normal human development. This 
starting point provides thus a phenotypic anchoring of the 
transcriptome data to be obtained.
In the present study, we selected the six most robust and 
novel hits for further characterization by transcriptome pro-
filing. They included the chemotherapeutics geldanamycin 
and arsenic trioxide, the flame-retardant PBDE-99, the pes-
ticide triadimefon and the histone deacetylase inhibitors 
valproic acid and trichostatin A. We performed a whole-
transcriptome analysis to detect changes triggered by these 
substances in human neural crest cells. Three main ques-
tions were asked: (1) can transcriptome profiles of NCC be 
used to identify DNT compounds; (2) how can transcrip-
tome information be reduced to toxicological profiles; (3) 
which are the possible approaches to identify candidate 
biomarkers from transcriptome profiles.
To answer these questions, the present study included 
a blind study, probing the predictivity of compound-tran-
scriptome pattern matching. Furthermore, we developed 
new visualization tools to display the toxicity pattern of 
each substance based on transcriptome data. Finally, we 
proposed two approaches to prioritize and select candidate 
biomarkers which led to the identification of 39 transcripts 
to be further explored as NCC toxicity indicators.
Materials and methods
Cell culture and neural crest differentiation
The reporter hES cell line H9-Dll1 (GFP under Dll1 pro-
moter) was provided by Mark Tomishima from the Memo-
rial Sloan Kettering Cancer Centre (MSKCC, NY, USA). 
Import of the cells and all experiments was carried out 
according to German legislation under the licence number 
1710-79-1-4-27 of the Robert-Koch Institute.
H9-Dll1 cells were maintained on mouse embryonic 
fibroblasts (MEFs) in DMEM/F12 (Gibco) medium con-
taining 20 % of serum replacement, HEPES (1 M, Gibco), 
l-gluthamine (Glutamax, Gibco), non-essential amino 
acids (MEM NEAA, Gibco), beta mercaptoethanol (Gibco) 
and basic fibroblast growth factor (10 ng/ml, Invitrogen).
Differentiation of hESC into neural crest cells (NCC) 
was initiated on Mitomycin C-treated murine bone marrow-
derived stromal MS5 cell line and continued as described 
in Zimmer et al. (2012).
Chemical exposure during NCC migration
hESC-derived NCC were exposed for 48 h to non-cyto-
toxic concentration of different NCC migration-inhibiting 
substances in N2 medium containing EGF (20 ng/ml) and 
FGF2 (20 ng/ml). Six compounds were used: geldanamy-
cin (16 nM, Selleckchem), arsenic trioxide (1 µM, Sigma-
Aldrich), thricostatin A (TSA, 10 nM, Sigma-Aldrich), 
valproic acid sodium salt (VPA, 250 µM, Sigma-Aldrich), 
triadimefon (100 µM, Bayer Crop Science) and pentabro-
modiphenyl ether (PBDE-99, 15 µM, Clickchem). Two 
different solvent control groups were also produced: NCC 
were exposed to 0.04 % DMSO or simply to N2 medium 
for 48 h. Finally, a third control group (exposed to N2 
medium only) was added specifically as control of arsenic 
trioxide, since the testing of this substance was performed 
not in parallel with the other compounds.
Affymetrix gene chip analysis
Samples of ≥5 × 106 cells were collected using RNA pro-
tect reagent from Qiagen. The RNA was quantified using 
a NanoDrop N-1000 spectrophotometer (NanoDrop, Wilm-
ington, DE, USA), and the integrity of RNA was confirmed 
with a standard sense automated gel electrophoresis system 
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(Experion, Bio-Rad, Hercules, CA, USA). Analysis was 
then performed as described earlier (Krug et al. 2013b) 
using Affymetrix chip-based DNA microarray (Human 
genome U133 plus 2.0 arrays) with all standard quality 
control procedures.
Biostatistics
The microarray data analysis (extrapolation and normali-
zation of the array sets) was performed using the statisti-
cal programming language R-version 3.1.1 as described in 
Waldmann et al. (2014). For the normalization of the entire 
set of Affymetrix gene expression arrays, the extrapolation 
strategy (RMA+) algorithm (Harbron et al. 2007) was used 
that applies background correction, log2 transformation, 
quantile normalization and a linear model fit to the normal-
ized data in order to obtain a value for each probe set (PS) 
on each array. As reference, the normalization parameters 
obtained in earlier analyses (Krug et al. 2013b) were used. 
After normalization, the difference between gene expres-
sion and corresponding controls was calculated (paired 
design). Differential expression was calculated using the 
R package limma (Smyth et al. 2005). Here, the com-
bined information of the complete set of genes is used by 
an empirical Bayes adjustment of the variance estimates of 
single genes. This form of a moderated t test is abbreviated 
here as ‘limma t test’. The resulting p values were multi-
plicity-adjusted to control the false discovery rate (FDR) by 
the Benjamini–Hochberg procedure (Benjamini 1995). As 
a result, for each compound a gene list was obtained, with 
corresponding estimates for log fold changes and p values 
of the limma t test (unadjusted and FDR-adjusted).
Transcripts with FDR-adjusted p values of ≤0.05 and 
fold change values of ≥1.8 were considered significantly 
deregulated and defined as differentially expressed genes 
(DEG).
Data display: heatmap and principal component 
analysis
The software R (version 3.1.1) was used for all calcula-
tions and display of PCA and heatmaps. Principal compo-
nent analysis (PCA) plots were used to visualize expression 
data in two dimensions, representing the first two principal 
components. The percentages of the variances covered are 
indicated in the figures. Heatmaps were used to visualize 
matrices of gene expression values.
The hierarchical clustering analysis was performed as 
previously described (Krug et al. 2013b). Complete link-
age was used as agglomeration rule for the clustering 
analysis. Distances based on the Euclidean distance meas-
ure were used to group together transcripts with similar 
expression patterns across samples (rows of the heatmap). 
Then, expression values within each row were normalized 
as Z-factors and colour-coded accordingly. Colour encodes 
the magnitude of the values as z score, ranging from blue 
(low) to yellow (high).
Support vector machine‑based classification
A support vector machine algorithm with linear kernel was 
used for the discrimination between two data sets: a train-
ing group composed of three biological replicates and a test-
ing group composed of two biological replicates (with com-
pounds blinded to the experimenter) using the same set of 
compounds. Both groups were normalized to the respective 
controls; i.e. the difference between gene expression and cor-
responding controls was calculated (paired design). Geldana-
mycin, PBDE-99 and triadimefon had common controls, val-
proic acid (VPA) and trichostatin A (TSA) were assigned to 
the same set of controls, and arsenic trioxide had its own set 
of controls. After subtracting controls, the number of varia-
bles was reduced to the 100 probe sets with highest variance 
within the training set. Then, in a second step, the hyperpa-
rameters for optimizing the decision boundary between the 
known training compounds were determined (using a grid 
search over supplied parameter ranges). These parameters 
were then used to generate the classification model to pre-
dict for the blinded testing sample the probabilities to belong 
to the known training compounds. For multiclass classifica-
tion with more than two classes, first in a ‘one-against-one’ 
approach, all possible binary classifiers were trained and 
corresponding probabilities were calculated from a logis-
tic regression as described in Rempel et al. (2015). Then, a 
posteriori class probabilities for the multiclass problem were 
obtained using quadratic optimization.
Gene ontology (GO) and KEGG pathway enrichment 
analysis
The gene ontology group enrichment was performed using 
R-version 3.1.1 with the topGO package (Alexa et al. 
2006) using Fisher’s exact test, and only results from the 
biological process ontology were kept. Here, again the 
resulting p values were corrected for multiple testing by the 
method of Benjamini–Hochberg (Benjamini 1995).
The KEGG pathway analysis was performed using the 
R package ‘hgu133plus2.db’ (Carlson 2015). Probesets are 
mapped to the identifiers used by KEGG for pathways in 
which the genes represented by the probe sets are involved. 
The enrichment was then performed analogous to the gene 
ontology group enrichment using Fisher’s exact test.
Up- and downregulated differentially expressed genes 
were analysed separately for each treatment. Only GO 
classes and KEGG pathways with a BH-adj. p value ≤0.05 
were considered significant.
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Toxicity pattern visualisation
ToxPi diagrams as developed in the ToxCast project (Klein-
streuer et al. 2011; Filer et al. 2014) were constructed using 
a Web-based user interface (Reif et al. 2013). For this pur-
pose, the numbers of DEG of overrepresented GO groups 
and KEGG pathways were normalized to the highest 
respective values for each category across all compounds 
(359 for DEG, 373 for GO classes and 17 for KEGG path-
ways). The ToxPi score was calculated over the six param-
eters used for ToxPi construction, with double weight given 
to KEGG and GO versus DEG.
GO classes and KEGG pathway terms were included 
only when ≥3 differentially expressed genes were found in 
the enriched term or (for small groups) when ≥50 % of the 
genes belonging to the GO/KEGG group were found to be 
significantly altered in our study.
GO superordinate classes distribution
The gene ontology group enrichment was performed as 
described above. Up- and downregulated differentially 
expressed genes were analysed together for each treatment. 
Only GO classes with a BH-adj. p value ≤0.05 were con-
sidered significantly enriched. Classic and elim methods 
(described in Alexa et al. 2006) were both used: classic 
method was chosen for geldanamycin treatment, while elim 
method was used for the analysis of the other compounds. 
The elim algorithm iteratively removes the genes mapped 
to significant GO terms from more general (higher level) 
GO terms, whereas the classic algorithm neglects the local 
dependencies between GO terms in its calculations.
Enriched GOs were then assigned to superordinate cell 
biological processes as already described in Waldmann 
et al. (2014) and distributed in six classes: migration/
adhesion, metabolism, differentiation, signalling, stress 
response and others. The migration class includes migra-
tion- and adhesion-related GO classes; stress response class 
includes cell death-, extracellular stressor-, inflammation/
immunity-related GO classes; signalling class consists of 
cell receptor activity-, second messenger (cAMP, cGMP, 
Ca2+) metabolism-, kinase modification-related GO 
classes. Metabolism class comprise all GO classes cover-
ing metabolism activity; differentiation class includes cell 
differentiation-related GO classes; ‘other’ class covers all 
the others: not otherwise classified GO classes.
Biomarker quality control
To evaluate how the here-chosen set of 39 biomarkers 
(set_A) compared to random combinations of 39 genes 
(set_Xi; i = 1–1,000,000), a simple metric for the separa-
tion power (controls vs six test compounds) of biomarker 
sets was developed and expressed as separation units (SU). 
The distribution of these SU was then determined by boot-
strapping (one million samples), and the relative position 
of set_A in this distribution was determined. The metric is 
based on the following procedural steps: (1) for each of the 
54,675 probe sets (PS), a T score was calculated for com-
parison of one of the six test compounds with the control 
(with n = 5 for controls and test compound samples); i.e. 
six T values were obtained for each PS [one for each of the 
compounds geldanamycin (GA), triadimefon (TDF), VPA, 
TSA, arsenic trioxide (As2O3) and PBDE]; (2) only the PS 
with at least one compound showing a difference from con-
trol with p < 0.05 were considered in further steps; (3) the 
T scores of the group of PS assigned to the same gene were 
averaged; (4) the genes were ranked according to their T 
scores. This was done individually for each test compound; 
then the ranks were normalized to a ranking value (‘r’; val-
ues from 0 to 1, where r = 0 corresponds to low T score 
[low grade of separation between control and exposure) 
and r = 1 to high T score (high grade of separation)]; (5) 
the rank values of 39 biomarker genes (of set_Xi or set_A) 
were averaged to give a ‘biomarker separation rank’ for one 
given compound; (6) the six biomarker separation ranks for 
the toxicants were assumed to define a vector in six-dimen-
sional space, indicating the distance of toxicants from the 
control. The length of this vector was used as metric for the 
SU:
The length of this vector was in the range 0–2.45. 
The randomly chosen set_Xi had an average SU of 
1.256 ± 0.081, and the set_A was at 1.75 (i.e. >6 SD larger 
than the average).
Results
Data structure of transcriptional changes induced 
in neural crest cells exposed to migration‑inhibiting 
concentrations of test battery hits
To explore the effects of neural crest toxicants on the tran-
scriptome, six compounds were selected that had been 
shown earlier to inhibit migration of human neural crest 
cells (NCC) in the MINC assay (Zimmer et al. 2014; 
Dreser et al. 2015). They comprised the heat-shock pro-
tein modifier and new chemotherapeutic lead compound 
geldanamycin (GA), the chemotherapeutic agent and 
environmental toxicant arsenic trioxide (As2O3), the bro-
minated flame-retardant PBDE-99, the triazole pesticide 
triadimefon (TDF) and the histone deacetylase inhibitor 
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To allow comparisons amongst the compounds, NCC were 
exposed for 48 h to each of the toxicants at their respective 
highest non-cytotoxic concentration and to solvent con-
trols. Then, mRNA was prepared from three different cell 
lots and used for gene expression analysis by Affymetrix 
microarray technology (Fig. 1a).
After initial data processing and quality controls, the 
gene expression data were used to determine the differ-
entially expressed genes (DEG). The DEG for each toxi-
cant were defined here as the group of microarray probe 
sets (PS), which differed significantly from negative con-
trols (FDR-adjusted p value ≤0.05) and showed expres-
sion level changes (fold change (FC)) of ≥1.8 or ≤0.55. 
On this basis, the toxicant effects could be roughly catego-
rized: strong effects on the transcriptome were observed 
for As2O3 (478 DEG) and PBDE-99 (443 DEG), a medium 
effect was detected for GA (93 DEG) and triadimefon (40 
DEG), while no effect was observed for TSA and VPA 
(0 DEG). Moreover, we observed three different types of 
response, concerning the direction of gene regulations: a 
predominant upregulation (ratio between upregulated DEG 
(DEG up) and downregulated DEG (DEG dw) ≥10 (e.g. 
GA); a predominant downregulation, with a ratio between 
DEG up and DEG dw of ≤0.1 (e.g. triadimefon); and 
mixed, bidirectional regulations (e.g. As2O3 and PBDE-99) 
(Fig. 1b).
To visualize the different gene expression profiles across 
all compounds and replicates, a principal component analy-
sis (PCA) was performed, based on the 100 PS with high-
est variance amongst the samples. Plotting of the first two 
principal components showed that the replicates of each 
compound clustered closely together, while the compounds 
clearly separated from the nine controls and from one 
another. As expected, the two ‘strong-effect’ compounds, 
As2O3 and PBDE-99, showed the most distinct separation 
from controls and from one another. Notably, also HDACi 
(TSA and VPA) separated clearly from controls, but they 
could not be separated from each other (Fig. 1c). This 
separation effect in the PCA (despite the absence of DEG 
for HDACi) was due to the combined use of an ensemble 
of 100 PS selected by highest variance amongst samples, 
instead of a gene-by-gene comparison.
In conclusion, the initial analysis of the microarray data 
showed that the quality of the gene expression data sets 
Fig. 1  Experimental design and transcriptome data structure of 
test battery hits. a Sampling for microarray analysis was performed 
in neural crest cells after 48-h exposure (red arrow) to non-cyto-
toxic and migration-inhibiting concentrations of six test battery hits 
(geldanamycin, arsenic trioxide, PBDE-99, triadimefon, TSA and 
VPA), as identified by the method and the data published in Zim-
mer et al. (2014). b The differentially expressed genes (DEG) were 
identified for each condition: the number of up- (DEG up) and down-
regulated genes (DEG down) are shown in the table (details can be 
found in the supplementary material; p values were FDR-corrected). 
c Principal component analysis (PCA) was performed, based on the 
100 transcripts with highest variance, and a 2D plot was generated to 
display the transcriptome data structure across compounds and exper-
imental replicates. Each point represents one experiment (= data 
from one microarray), where the chemical label supported by the col-
our coding indicates the compound and the form of the data points 
indicates the replicate. The percentages of the variances covered are 
indicated on the axes (colour figure online)
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was high enough for further exploration and that different 
migration inhibitors appeared to trigger distinct signatures 
of gene expression changes in NCC.
Computational toxicant identification based 
on correlation between transcriptome data sets
While the initial analysis suggested that a post hoc sepa-
ration of toxicants was possible to some extent, we were 
interested in the predictive power of the transcriptome 
analysis. For this purpose, the data sets obtained initially 
were used as training set of a classification rule, while new 
data for each compound (n = 2 additional experiments) 
were obtained as testing set (Fig. 2a). The ‘testing set’ 
experiments were performed in a way that it was known 
to the experimenter, of which samples were negative con-
trols, while the identity of the toxicants to be tested was 
blinded.
Fig. 2  Correlation analysis between ‘training set’ and blind ‘test-
ing set’ data. a Two data sets were generated: a training set, based 
on the data presented in Fig. 1 (boxes with capital letters, n = 3), 
and a testing set, based on data obtained by additional two replicates 
(with compounds blinded to the experimenter), using the same set of 
compounds (boxes with small letters, n = 2). Both groups were nor-
malized to the respective controls (Ctrl, orange boxes). b A PCA plot 
based on the 100 transcripts with highest variance was generated to 
display the structure of the transcriptome data of the testing set along 
the first two principal components. c The 100 probe sets with high-
est variance (‘100 PS’) within the training set were identified. Then, a 
classifier was built using the support vector machine (SVM) approach 
(see methods). Finally, the probabilities of the blinded testing sam-
ples to belong to the known training compounds were predicted. 
d The best and second best predictions, based on a support vector 
machine approach (indicated as relative probability in the brackets), 
are listed for each blind replicate (first column). The real identity 
of the samples (truth) is indicated in the last column. For instance, 
the highest probability (50 % likelihood) for blind sample d1 was 
obtained for geldanamycin (GA), and the second highest (16 % likeli-
hood) was for VPA. The unblinding of the sample revealed it to be 
GA (colour figure online)
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To obtain an overview over the new data, a PCA of the 
testing set microarrays was performed after ‘unblinding’ 
of the data to the person doing the analysis. The results 
showed that the structure of the collected transcriptome 
data resembled the one of the training set; i.e. all toxicant 
samples separated ‘visually’ from the six controls, and the 
couples of toxicant replicates were closer to one another 
than to other data points (Fig. 2b).
In the next step, the 100 probe sets with highest vari-
ance within the training set were used for the classifica-
tion analysis, in an attempt to identify the treatment of 
each of the blinded samples of the testing set. For this 
purpose, a support vector machine approach was used 
to discriminate between the six different compounds. 
The training set composed of three biological replicates 
was used to generate the classifier which includes (1) the 
selected probe sets, (2) the optimized hyperparameters of 
the model and (3) the classification rule for belonging to 
a particular compound. The classifier was then applied to 
obtain for each blinded testing sample the probabilities to 
belong to the known training compounds. The probabili-
ties were then sorted in descending order, and the training 
set condition yielding the highest probability of affiliation 
was taken as ‘best prediction’ for the corresponding test-
ing set data (Fig. 2c).
Nine out of twelve blind samples were correctly pre-
dicted (75 % predictivity); i.e. the correct compound was 
assigned to the respective microarray. All the ‘wrongly’ 
predicted samples belonged to the HDACi group, and pre-
dictions were correct within the group. If prediction of an 
HDACi was accepted as correct prediction for VPA or TSA, 
the overall predictivity of the test was 100 % (Fig. 2d).
The predictivity of the classifier was not affected by the 
separation of the five microarrays per compound into train-
ing and testing set: a simulation study was performed by 
random selection of the replicates belonging to the train-
ing or testing data sets: 1000 different combinations were 
analysed, and for all compounds, with exception of the 
HDACi group, ~100 % correct predictions were observed 
(Fig. S1A).
The prediction may suffer from a skewing of our com-
pound collection, as the two HDAC inhibitors formed a 
group amongst themselves and thus led to an overrepre-
sentation of a defined toxicological mechanism within the 
group. For this reason, we performed a second set of analy-
ses after exclusion of TSA from the compound set. In this 
new scenario, we reached 100 % predictivity, with 10 of 10 
correct predictions (Fig. S1B).
The outcome of this small blind-testing study suggests 
that microarray data may be useful to assign unknown com-
pounds to predefined groups of compounds, for instance, to 
obtain some initial toxicological information or for biol-
ogy-supported read-across.
Characterization of toxicant‑induced transcriptome 
profiles
To obtain more in-depth insight into the transcriptome 
changes induced by each compound, the training and test-
ing set data were combined and analysed together for DEG. 
The increase in the statistical power (due to the increase in 
replicate numbers; n = 5) allowed the detection of a higher 
number of DEG. For As2O3 (453 DEG) and PBDE-99 (525 
DEG) treatments, the increase was rather moderate, and for 
GA (365 DEG; nearly all upregulations) and triadimefon 
(142 DEG; mixed regulation pattern), the increase was sub-
stantial. The increased sensitivity of the analysis was par-
ticularly evident for TSA (277 DEG) and VPA (140 DEG), 
which mainly led to gene upregulation (Fig. 3a). The new 
PCA plot over all conditions (15 controls plus 6 × 5 toxi-
cant samples) showed that all compounds separated from 
controls and from one another, if the HDACi TSA and VPA 
were considered as one group (Fig. 3b).
The differential effects of the toxicants on gene expres-
sion were also evident from a heatmap display that shows 
the relative expressions of the 100 PS with largest variabil-
ity. This allowed some first insight on the level of individual 
genes. For example, a group of PS (n = 13) upregulated by 
geldanamycin only comprised the three cell cycle control-
lers such as ESCO1, ESCO2 (N-acetyltransferases involved 
in establishment of sister chromatid cohesion), MALAT1 
(Tripathi et al. 2013; Yang et al. 2013) and ATRX (Berube 
et al. 2000). Other examples are the group of PS who were 
specifically upregulated upon PBDE-99 treatment, such as 
the cytochromes CYP1A1 and CYP1B1 or tachykinin, or 
the 17 genes downregulated only by triadimefon (e.g. the 
inflammation-related factors MICB, endothelin and GBP1; 
Fig. 3c).
Encouraged by this visual exploration, the gene expres-
sion changes were explored quantitatively on the PS level. 
The DEG for each toxicant were sorted according to their 
p values and the top 20 up- and downregulated genes were 
selected. This approach focussed on the statistically most 
important regulations by each toxicant versus control 
Fig. 3  Overall transcriptome changes based on pooled data sets. a 
Training and testing expression data sets were analysed together to 
identify overall transcriptome changes. The number of differentially 
expressed genes significantly up- or downregulated is listed in the 
table for each condition (detailed data are shown in supplemental 
material). b The transcriptome data structure was displayed as prin-
cipal component analysis (PCA) 2D plot showing the first two prin-
cipal components. Percentages of covered variances are indicated on 
the axes. c The transcriptome data were represented as heatmap indi-
cating the gene expression values of the top 100 probe sets with the 
highest variability amongst the compounds. Expression values of the 
individual genes were transformed to z scores (along rows). On the 
right some exemplary gene groups are indicated for guidance (e.g. 
genes upregulated specifically by geldanamycin)
▸
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Fig. 4  Selection of the 20 most significant up- and downregulated 
genes for hit compounds. The differentially regulated genes were 
identified for six hit compounds and sorted according to their p value. 
The top 20 upregulated (green) and downregulated (red) genes for 
each condition are shown as bar graphs indicating the fold change 
(FC). Genes regulated with a FC below the threshold of 1.8 are indi-
cated in light red. Few example genes were chosen according to their 
toxicological/pathophysiological interest level according to the litera-
ture. This biased selection is displayed only as initial rough overview 
and food-for-thought for later marker selection (colour figure online)
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conditions, without taking into account whether other toxi-
cants affected the same gene (Fig. 4).
Arsenic trioxide affected many heavy metal-induced 
genes (upregulation of different metallothioneins (MT) 
isotypes; 30-fold upregulation of heme oxigenase-1), and 
it upregulated the protease inhibitor cystatin-A, similar to 
the situation observed in human T cells after treatment with 
arsenic (Shao et al. 2014). PS strongly downregulated by 
arsenite comprised CXCL14, a chemokine which is known 
to play a role in cell migration, and LRRC3B, a gene whose 
cord blood leucocyte DNA methylation pattern was found 
altered in a cohort of newborns prenatally exposed to arse-
nic in water (Rojas et al. 2015).
The exposure to geldanamycin led to a 20-fold upregula-
tion of PHLDB2. The product of this pleckstrin homology 
domain gene, also known as LL5β, is a protein implicated 
in migration and tumour cell invasion, by stabilizing of 
the protrusive activity at the cell front (Astro et al. 2014). 
Downregulations by geldanamycin were only moderate, 
and they comprised, e.g., the metalloproteinase MMP1 and 
the cell matrix proteoglycan PRG4.
Amongst the genes upregulated by PBDE-99, we iden-
tified neural pentraxin (NPTX1; ~20-fold upregulated), 
whose cognate protein exclusively localizes to the nervous 
system. Moreover, extracellular matrix factors involved 
in axon guidance were affected, like netrin 4 (NTN4) or 
the collagens, COL5A3 and COL15A1. The downregu-
lated genes comprised the thioredoxin-interactin protein 
(TXNIP), whose downregulation was also observed in 
HUVEC (Kawashiro et al. 2009) and H295R adrenocor-
tical carcinoma cells (Song et al. 2009) after exposure to 
polybrominated diphenyl ethers. Other examples of down-
regulations are contactin 1 (a neuronal membrane protein 
with functions in cell adhesion and the formation of axon 
connections in the developing nervous system) or NDST4, 
an enzyme involved in extracellular matrix (heparin) 
synthesis.
In triadimefon-treated cells, upregulations were very 
moderate. Amongst the most downregulated genes, we 
identified the ankyrin repeat domain (ANKRD1) as well 
as α and β actin. Moreover, the downregulated DEG com-
prised endothelin 1, which is involved in neural crest pat-
terning (Pla and Larue 2003). The attenuated activity of 
this gene may be related to the neural crest toxicity of the 
pesticide (Di Renzo et al. 2011; Menegola et al. 2005).
HDACi upregulated, e.g., myocardin, similarly as 
observed in forebrain precursor cells (Balmer et al. 2014), 
the cell adhesion molecule (L1CAM) and desmoglein, a 
cell–cell junction glycoprotein. Some of the top down-
regulated genes (LRRC3B and cadherin-8) were similar to 
those downregulated by HDACi in central neural precur-
sors (Balmer et al. 2014).
We also observed deregulation of a particular group 
of genes linked to neurocristopathies, a specific class of 
pathologies deriving from NCC deficits. Amongst the genes 
known to be linked to neurocristopathies, three groups 
were also affected by toxic chemicals: first, endothelin and 
its receptors (EDN1 and EDNRB; Kurihara et al. 1994), the 
expression of which was altered by all toxicants except for 
PBDE-99; the neurofibromatosis (NF) gene family (Naka-
mura 1995) which was altered specifically in geldanamy-
cin-treated NCC (NF1 and NF2); and the netrins (Amiel 
et al. 2008), which were altered in PBDE-99 (NTN4)- and 
TSA (NTN4 and NTNG)-treated cells.
This analysis on the level of individual genes/PS sug-
gested effects of the toxicants on very different pathways 
and biological processes (Fig. 4), but such more narrative 
descriptions are of limited use for toxicological hazard 
estimates and quantitative approaches. To explore options 
for quantifications of transcriptome changes, and for com-
parisons amongst compounds, we employed unbiased 
approaches to identify disturbed higher-order biological 
processes.
Visualization of toxicity patterns based on coordinate 
regulation of genes involved in joint superordinate 
biological processes
To compare the effects on the transcriptome regulation 
amongst the different conditions, a multidimensional rep-
resentation was chosen, as pioneered earlier, e.g., by the 
ToxPi approach in the ToxCast program (Reif et al. 2013) 
or by the use of toxicity indices developed on the basis of 
superordinate biological processes (Waldmann et al. 2014). 
Such descriptors go beyond the level of individual genes, 
by quantifying the regulation of entire gene ontologies 
(Theunissen et al. 2011, 2012; Waldmann et al. 2014) and 
forming aggregate measures or simplified visualizations.
In a first step, the pattern of transcriptome changes was 
visualized on the basis of six key parameters: the number 
of up- and downregulated DEG, the number of GO terms 
enriched amongst upregulated (GO up) and downregu-
lated DEG (GO dw) and the number of KEGG pathways 
enriched by upregulated (KEGG up) and downregulated 
DEG (KEGG dw; Figs. 5, 6). To facilitate comparisons, the 
underlying data were normalized across all compounds to 
the respective maximum value observed in the whole study. 
This procedure is similar to the one taken by EPA in their 
ToxPi approach, and it allows direct comparisons of the 
patterns observed in the radar plots used here. For instance, 
it becomes easily evident that TSA was characterized by 
overrepresented GO terms only amongst its upregulated 
DEG, while the reverse was observed for triadimefon (only 
GO terms amongst downregulated DEG). For information 
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beyond an initial overview, all detailed data were compiled 
in tabular form (Supplementary tables S1-3).
In a second step, the types of biological processes that 
may be linked to the altered transcriptome of toxicant-
treated cells were visualized. For this purpose, all DEG 
(up and down) were pooled for a given compound. Then, 
GO term enrichment analysis was performed by a statisti-
cal method, the so-called elim algorithm that eliminates 
‘redundant’ GO groups, i.e. such GO groups that con-
tain the same genes, but do not provide new information 
(so-called children GOs or parent GOs of a given term; 
Alexa et al. 2006). The resultant unique overrepresented 
GO groups were assigned to five superordinate cell bio-
logical processes (Waldmann et al. 2014): stress response, 
signalling, migration/adhesion, metabolism, differentia-
tion; those that could not be assigned were grouped under 
‘other’. The category ‘stress response’ combined all GO 
terms related to cell death, extracellular stress, inflamma-
tion and immunity; the ‘signalling’ category comprised 
GO terms related to cellular receptors, second messengers, 
Fig. 5  Alteration of superordinate biological processes by envi-
ronmental pollutants. Graphical display to visualize broad informa-
tion on biological changes, i.e. the toxicity patterns triggered by the 
compounds belonging to the class of ‘environmental pollutants’ (tri-
adimefon, arsenic trioxide, PBDE-99): the spider diagrams (on the 
left) indicate normalized numbers of upregulated and downregulated 
(dw) differentially expressed genes (DEG); of GO terms overrepre-
sented amongst DEG (GO); and of overrepresented KEGG pathways 
(KEGG). The absolute values used for normalization of each axis are 
indicated at the bottom of the figure. They correspond to the respec-
tive highest value for all 6 compounds. The ring diagrams on the 
right-hand side show the relative distribution of 6 superordinate bio-
logical processes (stress response, migration/adhesion, metabolism, 
differentiation, signalling and other) amongst the DEG. The data are 
based on the counting of non-redundant overrepresented GO terms 
(detailed table in supplemental material) within each superordinate 
biological process category (white numbers). Identification of over-
represented GO was done on the basis of all DEG (up- and down-
regulated). In the middle, examples of overrepresented biological cat-
egories (KEGG, GO) are shown (with number of regulated and total 
genes belonging to the specific group) and colour-coded according to 
the superordinate process
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hormones/neurotransmitters and kinase modifications/regu-
lations. The relative contribution of the different superor-
dinate processes to the altered transcriptome response was 
shown in form of ring diagrams. These allow, for instance, 
a quick overview that suggests that the response to arsenite 
(Fig. 5) is dominated by ‘stress responses’, while HDACi 
responses have a strong ‘signalling’ component (Fig. 6). In 
case, more detailed information is required, then this can be 
retrieved from tabular compilations (Supplementary table 
S4).
Altogether, these overview presentations of transcrip-
tome changes showed at the first glance that the three envi-
ronmental pollutants had very different effects on neural 
crest cells, although they all inhibited migration (Fig. 5): 
triadimefon had a relatively modest influence on the tran-
scriptome, compared to PBDE-99; while the latter one 
mainly upregulated transcripts, arsenite predominantly 
downregulated gene activity. However, arsenic trioxide 
also upregulated some transcripts and these pointed, for 
instance, to the activation of the p53 pathway, which has 
been implicated earlier in arsenite toxicity (van Vliet et al. 
2007).
The ‘toxicity patterns’ obtained for the drug-like group 
of test chemicals were characterized by a predominant 
upregulation of DEG and associated biological processes 
(Fig. 6). Geldanamycin upregulated genes related to ‘can-
cer’ KEGG pathways, but also focal adhesion, a process 
that may be related to the migration-inhibitory activity of 
this compound in neural crest cells.
The TSA toxicity pattern was mostly characterized by 
upregulation. Amongst the upregulated DEG, only few 
KEGG pathways were enrichment (e.g. cell adhesion mol-
ecule and TGF-β signalling pathway), but a high overrepre-
sentation of GO terms was found. These included ‘cardiac 
development’ as well as ‘steroid signalling’, and the latter 
two were also found for the related compound VPA. In gen-
eral, VPA triggered a much less pronounced transcriptome 
response. This is well in line with a relatively specific phar-
macological activity of this compound, although it is used 
at high concentrations in clinical settings, and its mode of 
Fig. 6  Alteration of super-
ordinate biological processes 
by drugs. Toxicity patterns 
triggered by the compounds 
belonging to the class of ‘drugs’ 
(geldanamycin, TSA, VPA) are 
presented as in Fig. 5. The spi-
der diagrams indicate normal-
ized numbers of differentially 
expressed genes (DEG), GO 
terms overrepresented amongst 
DEG (GO) and overrepresented 
KEGG pathways (KEGG). 
The absolute values used for 
normalization of each axis are 
indicated at the bottom of the 
figure. They correspond to the 
respective highest value for all 6 
compounds. The ring diagrams 
show the relative distribution of 
6 superordinate biological pro-
cesses (stress response, migra-
tion/adhesion, metabolism, 
differentiation, signalling and 
other) amongst the DEG. In the 
middle, examples of overrep-
resented biological categories 
(KEGG, GO) are shown (with 
numbers of regulated and total 
genes belonging to the specific 
group)
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action is supposed to affect the chromatin structure of a 
large number of genes.
Candidate biomarker identification
Several hits from the MINC assay had been used here for 
transcriptome analysis and for a proof-of concept study to 
blindly predict compounds within a given group. However, 
for the use of higher numbers of compounds, transcrip-
tome analysis is too expensive and time-consuming. Limi-
tation to particularly informative transcripts, here called 
‘candidate biomarkers’ would greatly facilitate alterna-
tive approaches by PCR or target-specific next-generation 
sequencing. Therefore, we used the DEG identified here 
to define biomarker candidates. We followed two different 
strategies to select appropriate genes (Fig. 7a).
The first approach was based on the concept that DEG 
found for several compounds would have a broader appli-
cability (and statistical validity). Therefore, we identified 
all genes, the expression of which was affected by 4 or 
more toxicants. We termed this group of 12 genes ‘joint/
general toxicant signature’ (Fig. 7b). Two of them (EDN1 
and SERPINE1) were shared by 5 compounds, while the 
other 10 were altered by four toxicants. For the assignment 
of genes to this group, we did not consider the direction of 
regulation. For instance, triadimefon downregulated most 
of the transcripts that were upregulated by the other com-
pounds, and the only of the consensus gene upregulated by 
triadimefon was downregulated by the other toxicants.
Our second approach to identify a pool of candidate 
biomarkers followed a ‘scoring approach’ (Fig. 7a). We 
considered each gene that was regulated by one of the six 
toxicants and then assigned it a certain importance score 
according to a filtering and ranking algorithm (Fig. 8a). 
Initially, DEG had to fulfil three minimum requirements to 
be considered for scoring: a |FC| ≥ 1.8, a p value ≤0.05 
(corrected for false discovery rate) and a control expression 
level clearly above the microarray noise level, i.e. a fluo-
rescence value of at least 5 after RMA normalization (on a 
log2 scale ranging from 3 to 15).
Genes were then evaluated based on three further selec-
tion criteria (measurability, statistical power and biological 
relevance) and scored accordingly. For instance, a scor-
ing point was assigned to a given gene, when additional 
related genes (e.g. belonging to same family or sharing 
same receptor) were found in the DEG list. We felt that 
such genes would have a higher value as biomarkers, as 
they reflect a regulation mechanism (coordinated regula-
tion of functionally linked genes) going on in treated cells. 
For the same reason, additional scores were given to genes 
Fig. 7  Biomarker identifica-
tion strategy and joint toxicant 
signature-derived gene list. a 
Two different approaches were 
adopted to identify candidate 
biomarkers in this study: a ‘joint 
toxicant signature’-approach 
based on the overlap of DEG 
amongst the compounds, and 
a ‘scoring’ approach based on 
the evaluation and weighting of 
each gene as described in Fig. 8. 
b The ‘joint toxicant signature’ 
approach led to the identifica-
tion of 12 genes which were 
regulated by ≥4 toxicants; their 
expression direction is indicated 
by red (downregulation) or 
green (upregulation) arrows. At 
the bottom, information is given 
on how many % of the DEG 
regulated by each compound 
are represented in the list of 
overlapping DEG (colour figure 
online)
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which were members of enriched GO classes and KEGG 
pathways.
Finally, the genes with a score ≥3 were shortlisted, 
and this pool of markers was saved for potential later 
use (Supplementary table S5). For extraction of a rea-
sonably small number of candidate biomarkers from this 
list, 8–12 genes per compound were selected manually 
(non-mathematical approach) in a way to (1) ensure a 
reasonable balanced across the six toxicants, (2) give 
preference to genes with high scores and (3) favour 
low p values. This resulted in a final group of 35 can-
didate biomarkers (Fig. 8b). Notably, eight genes of this 
group overlapped with the biomarkers that were selected 
based on their role as ‘joint toxicant signature’ (Fig. 8c, 
Fig. 8  Scoring flow chart and overlap between gene markers identified 
by the scoring and the joint toxicant signature approaches. a The algo-
rithm of the ‘scoring approach’ to identify candidate biomarkers was 
based on 4 different selection criteria groups: high-quality data, meas-
urability, statistical power and biological relevance (colour-coded). 
Genes were considered for the scoring, when they fulfilled minimum 
criteria (significance, expression level). Then, scores were given for 
each gene according to criteria as indicated. Genes with a score ≥3 
were shortlisted and used for further selection of a final list of candi-
dates with particularly low p values and balanced across the six toxi-
cants. b This approach led to the selection of 35 candidate biomark-
ers. Those amongst them also found by the ‘joint toxicant signature’ 
approach (Fig. 7) are marked in pink. c The overlap of different types 
of candidate biomarkers is shown in a Venn diagram, d and, for clar-
ity reasons, the ‘joint toxicant’ markers are explicitly displayed, with 
the overlapping ones also marked in pink. *The expression level is the 
absolute fluorescence value of each probe set (after RMA normaliza-
tion) which ranged on a scale from 3 to 15. **The ‘confirmation score’ 
indicated that >1 PS was regulated (in the same direction) for a given 
gene. ***The ‘related-gene score’ was applied when, for a given gene, 
additional related genes were found in the DEG list (belonging to same 
family or sharing same receptor) (colour figure online)
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d). Thus, this final part of the study yielded altogether a 
pool of 39 candidate biomarkers that are of interest for 
further evaluation in a larger toxicant screen to predict 
neural crest functional toxicity or to allow grouping of 
toxicants according to shared mechanisms/biomarker 
signatures (Fig. S2). A statistical evaluation of this bio-
marker set indicated that it showed differences between 
the toxicants, was clearly related to the cell biology of 
drug response and performed much better than randomly 
selected sets of markers (Fig. 9).
Fig. 9  Summary of observations and biomarker set characteristics. 
a The ToxPi diagrams were built using the ToxPi GUI (Toxicologi-
cal Priority Index graphical user interface) software tool developed 
in the ToxCast project (Reif et al. 2013). The numbers of up- and 
downregulated DEG, enriched GO classes and KEGG pathways were 
normalized (range from 0 to 1) to the respective highest values (359 
DEG up, 313 DEG dw, 373 GO up, 146 GO dw, 17 KEGG up and 7 
KEGG dw) for each category, across all the compounds. Each slice 
of the diagram contains several types of information: the distance 
from the centre, proportional to the normalized value of the com-
posing that slice; the width (in radians) indicates the relative weight 
of that slice in the overall ToxPi calculation. In our analysis, double 
weight was given to the KEGG and GO slices (80 % of the total), 
while DEG slices contributed with 20 % of the weight. The calculated 
ToxPi score is indicated for each compound (under each diagram) 
as parameter for potential developmental toxicity. b GO enrichment 
analysis of 39 biomarker candidates was performed using the GO 
elim algorithm. The most significant GO class is listed together with 
the genes, which contributed to its enrichment. c A 2D-PCA plot was 
constructed for the six toxicants, based on the expression data for the 
39 candidate biomarkers. The values for each gene were calculated 
as the median value amongst the probe sets specific for that particu-
lar gene. The analysis was performed using the freely available Web 
tool ClustVis (http://biit.cs.ut.ee/clustvis). The ellipses show the 95 % 
CI. d From the pool of differentially expressed genes in NCC treated 
with toxicants, 39 samples (= genes) were drawn at random 1 mil-
lion times. The separation strength (extent of separation of controls 
from the group of toxicants of these samples) was calculated (x axis; 
parameter ranges from 0 to 2.45), and the distribution was plotted. 
For comparison, the separation strength of the here selected bio-
marker set is indicated
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Discussion
In the present study, we analysed transcriptome changes 
triggered by six hits of the ESNATS test battery. The 
compounds examined here had been identified as poten-
tial developmental toxicants because of their ability to 
inhibit NCC migration at non-cytotoxic concentration and 
the working procedure of the ESNATS test battery (Zim-
mer et al. 2014; Dreser et al. 2015) required further char-
acterization, including transcriptome mapping. The tran-
scriptome data obtained here allowed the separation of the 
toxicants on a principal component map. Moreover, they 
allowed the assignment of unknown samples to the known 
set of compounds, based on a support vector machine 
classification algorithm. Finally, the types of biological 
changes, indicated by the altered transcriptomes, were vis-
ualized in diagrams focusing on altered superordinate bio-
logical processes.
In this study, three questions were asked to explore the 
usefulness of transcriptome changes for a toxicant test 
battery. The first question addresses a key issue of toxi-
cogenomics in general: can transcriptome profiles be used 
to identify hazardous compounds? Previous studies have 
shown that this is a highly demanding challenge and that 
a lot need to be learned on better design and evaluation of 
transcriptomics studies for such purposes (Thomas et al. 
2013; Grinberg et al. 2014; Bourdon-Lacombe et al. 2015; 
El-Hachem et al. 2015). Thus, this large issue needs to be 
approached in smaller steps. A main issue that became 
evident in our study is the large heterogeneity in transcrip-
tome responses triggered by compounds that all affect the 
same functional endpoint (NC migration). One reason may 
be that migration of cells is such a complex endpoint that 
compounds with very diverse modes of action can affect it; 
i.e. very different molecular initiating events will affect the 
same adverse outcome. This precludes any simple type of 
analysis, such as the identification of a joint gene derange-
ment pattern across all compounds. However, on the posi-
tive side, toxicants known to share a known mode of action, 
such as VPA and TSA, also showed a similar transcriptome 
response. This implies that it may be possible to use tran-
scriptome responses for toxicological grouping of com-
pounds; i.e. that an unknown compound may be assigned 
to a group of already known toxicants based on shared tran-
scriptome profiles. This would be an expansion of the read-
across approach, away from structure-based algorithms to 
the incorporation of variable biological information (Low 
et al. 2013; Patlewicz et al. 2014; Bal-Price et al. 2015; 
Berggren et al. 2015). The basis for this was explored here 
in a small pilot study to see whether an unknown chemical 
could be assigned within a small, but diverse group of toxi-
cants to its most related compound. The blind assignment 
of six compounds to the six known compounds worked 
surprisingly well, given the fact that only three microarrays 
per compound were used to build the classifier.
Given the situation that in vivo testing for developmen-
tal toxicity, and especially developmental neurotoxicity has 
serious issues concerning species extrapolation and sensi-
tivity (van Thriel et al. 2012; Smirnova et al. 2014), there 
is a large need to consider new approaches for risk assess-
ment or at least filtering of relevant compounds for further 
testing. One such approach is the consideration of key 
biological processes, such as neural crest migration (Bal-
Price et al. 2012; Kadereit et al. 2012) that can be tested in 
appropriate in vitro systems. Compounds that affect such 
key biological processes could be further investigated for 
transcriptome changes in the respective system, and this 
information may then be used to better define the mode 
of action, but also to read across to other compounds with 
known in vivo toxicities. Similar approaches have been 
tried with promising results across largely different sys-
tems, not only based on human cells, but, e.g., also using 
model organisms such as zebra fish (Hermsen et al. 2013). 
A more radical future way would be to compare toxicants 
based on their transcriptome profiles in well-characterized 
test systems rather than on their effects in animals. One 
condition for this is a high level of test system characteriza-
tion and quality control (Leist et al. 2010, 2012b; Crofton 
et al. 2011; Coecke et al. 2005). Beyond this, a large 
knowledge base needs to be collected on whether toxicog-
enomics signatures really can predict toxicity in a given 
test system. Until now, only few functional developmental 
toxicity assays have been evaluated in this direction, and it 
is unclear whether, e.g., neurite growth or neurite degenera-
tion assays (Volbracht et al. 1999; Stiegler et al. 2011; Krug 
et al. 2014) fulfil such conditions. Also for general neuro-
degeneration assays, there is still little information, as tran-
scriptome information needs to be obtained during a phase 
prior to cell death. Moreover, if generated from complex 
models, such as cocultures (Alepee et al. 2014; Efremova 
et al. 2015), it needs to be distinguished from the general-
ized inflammatory response (Falsig et al. 2004; Falsig et al. 
2006). If such conditions are fulfilled, as recent studies 
have shown in the case of damage triggered by MPP+ in 
human neurons, then toxicogenomics information can yield 
surprising new information and mechanistic insight (Krug 
et al. 2014) and a related in vivo study also revealed hith-
erto unsuspected genetic regulations (Maertens et al. 2015; 
Rahnenfuhrer and Leist 2015).
A second question addressed in this study is how pri-
mary transcriptome information; i.e. long lists of differ-
entially expressed genes can be reduced to a format that 
is easier to handle and that can be used for toxicological 
purposes. Classical toxicology has worked well with semi-
quantitative information that is judged for its significance 
by experts and that requires careful consideration of many 
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modulatory and circumstantial factors. For instance, stain-
ing of histological slides may indicate cellular changes 
characterized by eosinophilia, hypertrophy and lipid drop-
let accumulation, and experts have to decide on the type 
and level of hazard this indicates or whether this is rather 
an insignificant or adaptive change. A similar system of 
several dozen to hundreds of categories is required for toxi-
cogenomics, while dealing with 25,000 individual genes 
will not be possible. One composite measure is the number 
of DEG. It appears evident that the information content of 
such an endpoint is relatively low, although there is a high 
likelihood that compounds that do not deregulate any gene 
are relatively harmless, and chemicals that deregulate very 
large numbers of genes may be problematic. More infor-
mation may be obtained from the examination of biologi-
cally linked gene networks, i.e. genes belonging to one GO 
group of KEGG pathway. An increasing number of over-
represented GO terms/KEGG pathways (or other biologi-
cal motives) amongst the DEG would indicate a specific 
regulation of genes belonging to a certain cell function as 
opposed to random gene regulations. A summary of the 
changes across all study compounds can be obtained from 
such measures very quickly, e.g., in the form of ToxPi 
diagrams (Reif et al. 2013), or the associated ToxPi score 
(Fig. 9a).
Even more information may be gained by looking 
exactly into which pathways (KEGG) are regulated or 
which specific groups the regulated genes belong to. How-
ever, a compromise has to be found between the detail of 
information and the simplicity of an initial toxicological 
statement. The chosen solution was to show only num-
bers of superordinate biological processes together with 
few examples and a rough classification. In addition to this 
coarse-grained initial information layer, supplementary 
information can then answer details, where required.
Even for such standard approaches, some decisions have 
to be taken. They include the statistical criteria used to 
define the DEG, but also involve issues such as the separate 
or combined treatment of up- and downregulated genes. We 
decided here to identify overrepresented GO and KEGG 
separately in the two groups of genes. With this procedure 
we followed an established routine that was chosen to facil-
itate comparisons amongst different conditions, such as 
different concentrations of one compound, or one concen-
tration of different compounds, or different exposure times 
of one compound (Krug et al. 2013b; Balmer et al. 2014; 
Waldmann et al. 2014; Rempel et al. 2015). When defining 
intersection between conditions, we felt that it is important 
to consider the direction of regulation of a gene and also to 
mine the genes accordingly for overrepresented biological 
themes. A different situation is encountered, when no such 
comparisons are intended and when different directions of 
regulation, e.g., within a GO group make biological sense 
(e.g. ‘positive regulation of apoptosis’ involves upregula-
tion of apoptosis inducers (BCL-2, caspases) and down-
regulation of inhibitors (BAX, IAPs, HSP70; Latta et al. 
2000; Gerhardt et al. 2001; Hansson et al. 2003). For this 
reason, GO analysis to identify superordinate biological 
processes was performed differently than for the general 
data exploration.
The third major question was directed to the identifica-
tion of biomarker candidates that would allow a simplified 
approach, compared to whole-genome transcript profiling. 
The term ‘biomarker’ has a wide range of implications and 
uses and therefore requires some definition in the context 
of our study. Very strict definitions are found in the field of 
predictive medicine, or in toxicology in the form of a bio-
marker of toxicity (BoT) that is required to have a high pre-
dictive value and to show some causal relationship with the 
adverse outcome (Blaauboer et al. 2012) or a toxicity path-
way (Leist et al. 2008). At the other end of the spectrum, 
biomarkers are simply seen as any endpoint that changes 
in a test system upon exposure to a test compound. An 
approach somewhere in between these extremes is to define 
biomarkers as preselected endpoints with a certain infor-
mation value concerning the study purpose (e.g. biomarker 
of exposure or biomarker as part of a predictive gene signa-
ture), but not necessarily linked to the mechanism of action 
of a compound. A good example for this type of approach 
is the GARD assay for skin sensitization (Johansson et al. 
2013, 2014), in which first whole-transcriptome data were 
obtained on skin sensitizers and negative controls, and 
then a statistics-based algorithm was applied to select the 
set of genes (biomarkers) that was most useful as classi-
fier. Similar approaches have been taken to add biological 
information for read-across, for instance, in the SEURAT-1 
research project on prediction of cosmetics toxicity (Gocht 
et al. 2015) or based on the TG-GATES transcriptome data 
(Low et al. 2013). We provided here a basis for such a latter 
approach by selecting a small number of genes from all the 
DEG of the study.
These were termed here ‘candidate biomarkers’ as more 
work is required to qualify them as ‘real’ biomarkers at 
a confidence level of, e.g., the GARD assay. An immedi-
ate usefulness is suggested by analysis of overrepresented 
GO terms amongst the 39 selected genes: the most signifi-
cant enriched GO class was ‘response to drug’ (Fig. 9b). 
Moreover, the chosen set of genes provided a good basis 
for separation of the study compounds from control cells 
(Fig. 9c, Fig.S3, Supplementary table S6). To obtain an 
idea on the performance of the selected biomarkers, rela-
tive to random sets of biomarkers, we use here a relatively 
simple and transparent approach to define ‘separation 
strength’, and we explored this separation strength of our 
biomarker set, when compared to one million sets, ran-
domly chosen from the pool of all regulated probe sets of 
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this study. The 39 biomarker sets were by far superior to 
random sampling (99–100th percentile of the distribution, 
with 6 standard deviations distance to the means; p < 10−6; 
Fig. 9d), which confirms the overall usefulness of our 
selection approach. We are aware of the relatively extreme 
assumptions we had to make (e.g. statistical independ-
ence of the endpoints), and that separation strength may 
be defined in many other ways. However, we hope that this 
initial attempt will trigger more work in this area, allow-
ing establishing criteria for separation strength of a set 
of biomarkers (as opposed to a classifier formula). In the 
future, a consensus will then need to be reached on statisti-
cal approaches to judge the quality of a given biomarker 
set relative to randomly selected sets.
At present, the explorative approaches discussed here 
qualify our small set of candidate biomarkers for further 
exploration and possible substitution of the full microar-
ray approach by a cheaper and faster technology. Three 
major steps will have to be taken towards this objective 
in the future: (1) the marker gens would require confir-
mation by the alternative analytical technology chosen 
(e.g. PCR) on the set of study compounds used here; (2) 
then, they would need to be tested for their usefulness on 
another set of compounds (Leist et al. 2010; Crofton et al. 
2011); (3) and finally, the time and concentration relation-
ship of marker changes would need to be correlated with 
the functional toxicity (inhibited migration) in the MINC 
assay.
In summary, this study added information on ESNATS 
test battery hits and provided a case study on the predictive 
value of toxicogenomics by showing that chemicals can be 
predicted, based on their transcriptome changes, at least 
within a smaller group. Extension to more compounds will 
be necessary. Moreover, tools were developed to visualize 
transcriptome changes and to provide at least semiquantita-
tive data on the extent and type of transcriptome derange-
ment. Finally, two different approaches were combined to 
preselect biomarkers that are still able to separate the com-
pounds and that will require further evaluation for their 
application in predictive toxicology.
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